Replies to post #138474 on Biotech Values

[jq1234]

Don't say DMC wouldn't stop early unless... Sutent stopped early in pNET a little bit prematurely which was major discussion during ODAC. It got a pass due to rare indication. We'll have to see the OS data on Zytiga, and OS with placebo crossed over to Zytiga.

[Summer2762]

I have a hard time believing the trial wouldnt have hit the OS endpoint if given a little more maturity.

This abi trial had a higher (practical) hurdle than the usual. In practice (not per protocol), not only the trial had to show good OS benefit by reaching statistical significance, the OS benefit had to be better than abi's post-chemo benefit.